Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 33 of 1,261
  1. US 12344596

    Solid forms of (S)-1-((2′,6-bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine and salts thereof

    LEXICON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  2. US 12344654

    Mage A4 T cell receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  3. US 12345709

    CLAUDIN18 antibodies and methods of treating cancer

    The Regents of the University of California · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  4. US 12344842

    Compositions and methods for treating and preventing macular degeneration

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  5. US 12344578

    Salt forms of bempedoic acid and methods for using the same

    Esperion Therapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  6. US 12343432

    Encapsulated probiotic

    UNITED ARAB EMIRATES UNIVERSITY · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  7. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  8. US 12344677

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  9. WO 2025133253

    EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE

    ABLYNX NV [BE] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  10. WO 2025133166

    VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE

    ABLYNX NV [BE] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  11. WO 2025137347

    FORMULATIONS DE RISANKIZUMAB À HAUTE CONCENTRATION

    ABBVIE INC [US] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  12. WO 2025133252

    DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5

    ABLYNX NV [BE] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  13. WO 2025132620

    PRÉPARATIONS DE CAPSULE MOLLE STABLES À REMPLISSAGE SOLIDE POUR PRINCIPES ACTIFS SENSIBLES À L'HUMIDITÉ

    BAYER CONSUMER CARE AG [CH] · Granted Jun 26, 2025 · Expires Jun 21, 2045

    granted
  14. US 12336983

    Inhibition of crystal growth of roflumilast

    ARCUTIS BIOTHERAPEUTICS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  15. US 12336995

    Combination therapies

    Mirati Therapeutics, Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  16. US 12337019

    Vehicles for applying bacteria to skin, scalp, and hair

    Northwestern University · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  17. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  18. US 12336973

    Cancer therapeutic compositions and methods targeting DNAse1L3

    Providence Health & Services—Oregon · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  19. US 12338459

    DNA-chimeric antigen receptor T cells for immunotherapy

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  20. US 12336982

    Compositions and methods of modulating short-chain dehydrogenase activity

    The Board of Regents of the University of Texas System · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  21. US 12336980

    Dosing regimen for a selective S1P1 receptor agonist

    VANDA PHARMACEUTICALS INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  22. US 12338269

    IL-2 superagonists in combination with anti-PD-1 antibodies

    Medicenna Therapeutics Inc. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  23. US 12337020

    Bacteriophage compositions

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  24. US 12336835

    Neuromodulation to target glucose transporter and/or incretin pathways

    GE Precision Healthcare LLC · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.